Drug
Cabergoline clinical trials
Also written Dostinex, Cabaser and FCE 21336.
- studies test it
- 51
- open now
- 11
- in phase 3
- 16
- first study started
- 2001
Keep track of what changes. Save the Cabergoline studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
51 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 18
- Phase 3
- 16
- Phase 4
- 8
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 45
Stanford University (3) · Benha University (3) · Northwestern University (2) · Boston Children's Hospital (2) · Par Pharmaceutical, Inc. (2) · University of Sao Paulo General Hospital (2) · Pfizer (2) · St. Olavs Hospital (1)
Often tested with
Tested in the same studies.
Metformin (2) · Levodopa (2) · Pyridoxine (1) · Calcium Gluconate (1) · Octreotide (1) · Pegvisomant (1) · Calcium Dobesilate (1) · Pasireotide (1)
Studies
Open first, then newest update. How each study uses Cabergoline is read from its arms, and is right about nine times in ten.
Testing it · 51
- Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast SymptomsRecruitingPhase 2Jefferson DrapkinNCT07492160Written as Cabergoline
- Combination Osilodrostat and Cabergoline in Cushing's DiseaseEnrolling by invitationPhase 4University of BasrahNCT07603466Written as osilodrostat and cabergoline
- Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesEnrolling by invitationNot applicableEnhanced Emirates LimitedNCT07568574Written as Cabergoline
- Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation SyndromeRecruitingPhase 2Tanta UniversityNCT07043322Written as Cabergoline
- Safety and Potency of a High Cabergoline Dosage in MicroprolactinomasRecruitingPhase 3University of Sao Paulo General HospitalNCT07463235Written as Cabergoline
- Carbergoline for Antipsychotic Induced Hyperprolactinemia.Not yet recruitingPhase 4Zealand University HospitalNCT07386080Written as Cabergoline (Dopamine Agonist)
- Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOSRecruitingNot applicableMst.Sumyara KhatunNCT07255911Written as Cabergoline 0.5 mg
- Cabergoline for Episodic MigraineRecruitingPhase 2Aarhus University HospitalNCT07072910Written as Cabergoline 0.5 MG
- A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate TabletsRecruitingPhase 3Changchun GeneScience Pharmaceutical Co., Ltd.NCT07124221Written as Cabergoline tablets
- Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist TreatmentRecruitingPhase 4University Hospital, Basel, SwitzerlandNCT07045935Written as Cabergoline (Dopamine Agonist)
- Cabergoline in the Management of Nonfunctioning Pituitary AdenomaEnrolling by invitationPhase 4National Taiwan University HospitalNCT07034859Written as Cabergoline 0.5 MG
- Pharmacological Inhibition of Lactation After 16 to 20 Week AbortionCompletedPhase 4Northwestern UniversityNCT06123026Written as Cabergoline
- Dopamine Agonist Treatment of Non-functioning Pituitary AdenomasActive, not recruitingPhase 3St. Olavs HospitalNCT02288962Written as cabergoline
- A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy LossWithdrawnPhase 2Stanford UniversityNCT06909123Written as Cabergoline
- Cabergoline for the Treatment of Chronic Pain Due to EndometriosisCompletedPhase 2Boston Children's HospitalNCT03928288Written as Cabergoline 0.5 MG
- Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy LossCompletedPhase 2Stanford UniversityNCT06029673Written as Cabergoline 1 MG
- Cabergoline as a Preventive Treatment for Chronic MigraineCompletedNot applicableUniversity of AarhusNCT05525611Written as Cabergoline 0.5 MG
- Cabergoline for Lactation Inhibition After Second-Trimester Abortion or LossCompletedPhase 2Stanford UniversityNCT04701333Written as Cabergoline 1 MG
- Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOSCompletedPhase 2Al-Rasheed University CollegeNCT05981742Written as Cabergoline 0.5 MG
- Lactation Inhibition, the Efficiency of Vitamin B6 Versus CabergolineCompletedNot applicableHaEmek Medical Center, IsraelNCT05024422Written as Cabergoline
See all 51 studies that test Cabergoline →
Given in every arm · 3 — Cabergoline is usual care beside what is tested
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedPhase 4RECORDATI GROUPNCT01794793Written as Cabergoline
- Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsCompletedPhase 4Novartis PharmaceuticalsNCT01278342Written as cabergoline
- Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome PreventionCompletedEarly Phase 1Hospital de CrucesNCT01530490Written as Cabergoline and Hydroxyethyl Starch
As the comparator · 3 — what is tested is compared with Cabergoline
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and CabergolineNot yet recruitingPhase 1Yanping KongNCT07732387Written as Cabergoline 0.5 MG
- Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation SyndromeCompletedPhase 2Aljazeera HospitalNCT02875587Written as Cabergoline
- Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation SyndromeStatus unknownPhase 2Aljazeera HospitalNCT02461875Written as Cabergoline
Codes
What other systems call Cabergoline · ClinicalTrials.gg INT006730
- MeSH (NLM) D000077465CabergolineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) LL60K9J05TCABERGOLINEConfirmed FDA, NLM, Wikidata
- RxNorm 47579Confirmed FDA, Wikidata
- Wikidata Q423308cabergolineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47428CabergolineOne source FDA
- DrugBank DB00248One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077465 | Cabergoline | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | LL60K9J05T | CABERGOLINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 47579 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423308 | cabergoline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47428 | Cabergoline | One source FDA |
| DrugBank | DB00248 | — | One source Wikidata |
Also registered as cabergoline diphosphate (UNII 477M7SA9N9).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.